BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Duke-NUS Launches LIVE Ventures: S$20M to Commercialize Academic Research

Duke-NUS Medical School launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative acad...

July 22, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

July 17, 2024 | News

Full-Life Technologies and SK Biopharmaceuticals Ink $571.5 Million Deal for Exclusive Rights to Radiopharmaceutical FL-091

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced that it has entered into a license agreement wit...

July 17, 2024 | News

Biosyngen's Groundbreaking CAR-T Therapy BRG01 Approved for Phase II Clinical Trial in China

Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...

July 17, 2024 | News

Sabin Vaccine Institute Launches Phase 2 Trial for Sudan Ebolavirus Vaccine in Uganda

Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine against Sudan ebolavirus, with healthy volunteers receiving the single-...

July 16, 2024 | News

Everest Medicines Announces Positive Topline Data from Phase 3 Trial of Etrasimod for Ulcerative Colitis in Asia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

July 16, 2024 | News

Senhwa Biosciences Submits IND to FDA for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemother...

July 15, 2024 | News

MSD Completes Acquisition of Eyebiotech Limited, Expands Late-Stage Pipeline with Promising Retinal Disease Treatment

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). ...

July 15, 2024 | News

National Cancer Center and University of Pennsylvania License CCR4 CAR-T Cell Therapy to ARC Therapies Inc.

The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a ch...

July 12, 2024 | News

Thermo Fisher and NCI Join Forces to Accelerate Precision Medicine Trials for AML and MDS

To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: T...

July 12, 2024 | News

Aptamer Group's CTO Arron Tolley Discusses Strategic Milestones and Innovations in Collaboration with AstraZeneca

In an exclusive interview with BioPharma APAC, Arron Tolley, Chief Technology Officer of Aptamer Group, shares insights on the company's latest col...

July 11, 2024 | News

Telix Pharmaceuticals Applauds CMS Proposed Changes to Improve Payments for Diagnostic Radiopharmaceuticals

Telix Pharmaceuticals welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective...

July 11, 2024 | News

Thermo Fisher Scientific Opens First Electron Microscopy Demo Center in Taiwan to Propel Semiconductor Innovation

To support next-generation semiconductor and materials innovation, Thermo Fisher Scientific today announced the opening of its first electron microscopy de...

July 10, 2024 | News

Sirnaomics Announces Positive Interim Results for Phase I Clinical Study of RNAi Therapeutic STP122G Targeting Factor XI

Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engagin...

July 09, 2024 | News

Stay Connected